The company was founded at the end of 2017 by Jeroen ter Schiphorst and Teun Wagenaar. Learn about who we are and what we do to make improvements in life possible. Read up on our latest press releases or peruse our various media archives. QIAGEN and INOVIO in 2019 announced a collaboration to develop a companion diagnostic to guide clinical decision-making for the use of INOVIOs DNA-based immunotherapy to treat cervical dysplasia caused by HPV. If you have questions about QIAGEN, our products or your order, this page should help you find the answers and contacts you need. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. The company added two new offices in the Asia Pacific region in New Delhi, India and Taipei, Taiwan. In addition, QIAGEN markets a range of gene panels for research applications in next-generation sequencing, covering dozens of genes associated with various cancers. rapidly bringing to market precisely designed DNA medicines to treat and protect people from, associated with HPV. Its who we are. Qiagen Company Profile - Office Locations, Competitors, Revenue - Craft Learn about easy ordering options that offer fast and reliable delivery. and stabilize, extract and purify various molecules of interest such as DNA, RNA or proteins from other cellular components. [citation needed], QIAGEN technologies can be used to identify genes that participate in the emergence of diseases, carry out studies on the functions and interactions between genes (or proteins) in entire biological pathways, identify and validate potential biomarkers and identify and evaluate therapeutic target molecules and suitable active agent candidates. Recognizing the rising needs our industry faces we are open to collaborative partnerships to better serve our customers, and we look forward to expanding our partner program well beyond our five new partners.. [29] In October 2019 QIAGEN entered into an agreement with Illumina granting QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina's diagnostic instruments. Expert-curated genomic and clinical knowledge, bioinformatics software and services for actionable insights from basic research to patient care! The QIAseq Normalizer Kit speeds up equalizing DNA concentrations across . The World Health Organization (WHO) reported an estimated 570,000 new cases of cervical cancer and 311,000 deaths in 2018. (PDF) QIAGEN Genomic DNA Handbook | Leia Torres - Academia.edu (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute. 1,613 views September 24, 2021 01:15:41 Discovery and Research Calling, annotating and investigating genomic variants using QIAGEN CLC. See insights on Qiagen including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. This press release contains certain forward-looking statements relating to our business, including our plans to develop, manufacture and commercialize DNA medicines, in particular our candidate VGX-3100 and a companion diagnostic in collaboration with QIAGEN, and our expectations regarding our research and development programs. Thank you for choosing QIAGEN. News, testing solutions and stories covering global efforts in the fight against COVID-19. The cervical dysplasia program is in late Phase 3 clinical trials (REVEAL1 and REVEAL2). Analyze. QIAGEN is targeting market segments with promising growth opportunities. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. The information will not be sold to any third party. [21] QIAGEN also acquired Enzymatic enzyme solutions. introduce you to CLC Genomics Workbench 12.0, which is the latest Clinical Analysis and Interpretation Services, Long-read sequencing analysis in the QIAGEN CLC Genomics Workbench. . QIAGEN is contributing an extensive track record of developing and commercializing novel diagnostic tests, said Dr. J. Joseph Kim, INOVIOs President and CEO. PGDx elio tissue complete is a first of its kind FDA cleared kit to enable any molecular lab to perform comprehensive tumor profiling, allowing our customers and partners to produce variant interpretation that maximize the value of NGS data in clinical care,. [13], In 2010, QIAGEN acquired ESE GmbH,[14] giving the company access to point of need testing devices for the application of molecular diagnostic tests without laboratory infrastructure. Discover a convenient way to design experiments and get all the products you need in one place. tv.qiagenbioinformatics.com The main operative headquarters are located in Hilden, Germany. [19] QIAGEN also acquired CLC bio, which offers bioinformatics analysis software. The portfolio encompasses assays for the detection of individual pathogens such as Influenza, HIV, Hepatitis, and healthcare-associated infections. QIAGEN Discovery Bioinformatics Services | QIAGEN Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed, cleared high-risk HPV 16 and 18 in a Phase 2b, cancer, 91% of anal cancer, and 69% of vulvar, cancer. Extend your in-house resources with the expertise, powerful bioinformatics and custom services that you expect from QIAGEN. For isolation of genomic, mitochondrial, bacterial, parasite or viral DNA, For automated purification of DNA from forensic and HID samples on the EZ1 Adv XL or EZ2 Connect Fx Instruments, For purification of genomic, mitochondrial or viral DNA from blood and other body fluids, For automated purification of high-quality DNA from 124 samples per run, For automated purification of DNA from 196 samples on the QIAsymphony SP Instrument, For extraction of total cellular DNA from plant cells and tissues or fungi, or genomic DNA from plant cells, tissues and seeds, For purification of genomic DNA from formalin-fixed paraffin-embedded tissues, For automated high-throughput isolation of total DNA from blood, cells, and tissues, For automated analysis of DNA fragments using QIAxcel instruments, For purification of archive-quality DNA from a wide variety of sample types, For efficient recovery of high-quality genomic DNA (gDNA) from formalin-fixed paraffin embedded (FFPE) tissue, For isolation of up to 20 g, 100 g or 500 g high-molecular-weight DNA from blood and cultured cells, For scalable isolation of genomic DNA from whole blood, buffy coat, and cultured cells in a single tube, For purification of residual host cell DNA and viral nucleic acids from bioprocess samples, For purification of up to 500 g genomic DNA from whole blood, For isolation of high-molecular-weight genomic DNA, For isolation of up to 20 g, 100 g or 500 g high-molecular-weight DNA from a wide range of samples, For automated high-throughput DNA purification from swabs, For the isolation of inhibitor-free DNA from a variety of cultured foods, For rapid isolation of genomic DNA from solid tissue samples, For efficient, high-throughput, manual or automated purification of total cellular DNA from plant tissue, For automated medium- to high-throughput purification of forensic DNA on the BioRobot Universal System, For purification of DNA from tissues fixed and stabilized in PAXgene Tissue Containers. NEW YORK - Qiagen and Verogen said on Tuesday that they have signed a partnership to provide laboratories with tools and support for next-generation sequencing-based human identification workflows. The goal is to increase the absolute efficacy of the immunotherapy.". PDF DNA Isolation with Qiagen Genomic-Tips - National Cancer Institute In September 2021, QIAGEN entered the DAX (Deutscher Aktienindex) Germanys leading stock market index. For a more eco-friendly alternative to our standard kit for extracting total DNA from animal blood and tissues, cells, yeast, or bacteria. Genomic Services - QIAGEN Products Find products for your experiment Discovery & Translational Research DNA & RNA Purification DNA Cell-Free DNA DNA Clean Up Genomic DNA Microbial DNA Plasmid DNA RNA Cell-Free RNA Microbial RNA miRNA mRNA RNA Clean Up Total RNA Multianalyte & Virus Instruments & Equipment Protein Purification Dummy field DO NOT USE/ DELETE/ MODIFY Needs to be hidden in CSS on LP, If Opp Type is INSTRUMENT // For SP creation / could be hidden field. Qiagen - Wikipedia QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. [citation needed], QIAGEN introduced the first kit for purification of plasmids small ring-shaped DNA molecules in bacterial cells in 1986, cutting the preparation time for plasmids from between two and three days down to two hours. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) and our commercial partners solely for the purposes of data hosting, phone calls and QIAGEN email distribution. QIAGEN today announced the launch of the QIAGEN Digital Insights Partnership program for genomic vendors to leverage QIAGENs genomic content and analysis leadership to expand customer access and deliver extended genomic solutions for scientists and clinicians. From RNA-seq and DNA-seq to multimodal and epigenetics applications, QIAseq NGS solutions and QIAGEN Genomic Services are designed to deliver accurate results from even the most challenging of samples while ensuring . +49 2103 29 11711, U.S. We are pleased to support INOVIO by developing companion diagnostics to identify patients who would benefit from VGX-3100. Two years later, QIAGEN launched its first product. Under the partnership, Qiagen obtains the rights to globally distribute current and future Verogen products. Um sich fr E-Mail-Benachrichtigungen fr Anleger anzumelden, geben Sie bitte Ihre E-Mail-Adresse in das unten stehende Feld ein und whlen Sie mindestens eine Benachrichtigungsoption aus. INOVIO is developing VGX-3100 as a non-surgical treatment for cervical pre-cancer and pre-treatment biomarkers we have discovered could be a targeted way to identify patients most likely to respond to treatment. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. The holding (QIAGEN N.V.) is located in Venlo, The Netherlands. National Institutes of Health, National Institute of Allergy and Infectious Diseases. Automation solutions tie these together in seamless and cost-effective workflows. We are on a mission to help society advance towards the sustainable production of goods. By providing your email address below, you are providing consent to QIAGEN N.V. to send you the requested Investor Email Alert updates. The company offers an unmatched depth and breadth of technologies from polymerase chain reaction (PCR) to next-generation sequencing (NGS) for companion diagnostic development. With more than 30 years delivering highly curated and quality genomic content and analysis through applications, such as QIAGEN IPA, QIAGEN OmicSoft, QIAGEN CLC, and QCI Interpret, QDI is expanding its partner network to enrich the current portfolio of analysis and interpretation offerings for researchers and clinicians. According to QIAGEN, the company's current portfolio covers more than 500 products and more than 2,000 patents and licenses. Furthermore, the company offers technologies for the extraction and enrichment of molecular biomarkers from body fluids, supporting the development of liquid biopsies. Purification of DNA using the QIAamp MinElute Media Kit can be automated on the QIAcube Connect. Looking for a quick way to design experiments. For spin-column or 96-well extraction of total DNA from animal blood and tissues and from cells, yeast, bacteria, or viruses. February 24, 2021 Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions QIAGEN's bioinformatic expertise raises predictive biomarker power in INOVIO's patient selection ), The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from clinical use of VGX-3100, INOVIO's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus (HPV). QIAsymphony DSP Virus/Pathogen Kits enable sensitive detection of a broad range of DNA and RNA viruses, as well as bacterial DNA[citation needed], In 2011, QIAGEN acquired Ipsogen S.A. for US$101 million,[15][16] adding to the company's product and IP portfolio in the blood cancer space and developing its position in molecular diagnostics for oncology. [8] QIAGEN's shares are listed at the NYSE (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). A kit for the purification of plasmids small ring-shaped DNA molecules in bacterial cells cutting the preparation time for plasmids from between two and three days down to two hours. Multimodal Cancer Genomics Profiling Services. Microbiome Profiling Services. Transparent, evidence-based NGS interpretation and reporting. Terms & Conditions. Genomic Services - QIAGEN [38], Resulting from the failed takeover bid, QIAGEN announced it would buy the outstanding 80.1% of shares in NeuMoDx Molecular Inc,which it did not already own for about $234 million.[39]. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. 01:31:30 QIAGEN CLC Genomics De novo assembly, BLAST and genome finishing using QIAGEN CLC Genomics Workbench 658 views June 27, 2023 01:32:24 QIAGEN CLC Genomics Antimicrobial resistance (AMR) and multi-locus sequence typing (MLST) using QIAGEN CLC Genomics Workbench 12 views June 08, 2023 01:20:59 QIAGEN CLC Genomics To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. [23] In late 2015 the GeneReader NGS System was launched,[24] and the acquisition of Mo Bio Laboratories was completed. Read up on our latest press releases or peruse our various media archives. Qiagen N.V. - QIAGEN and INOVIO expand collaboration to develop next Associate Director Public Relations, Lisa Mannagottera HPV is the most common viral infection of the reproductive tract and the fourth most common cancer among women. [citation needed]. [35] Davidson Kempner subsequently increased their holdings from 5.1% to 7.3% of QIAGEN.[36]. The new partnership program is still welcoming additional partners. Because of the lapsed offer, QIAGEN was required to reimburse $95 Million to Thermo Fisher in expenses. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ?unsubscribe? 1,295 views June 01, 2021 53:15 Tutorials Under the partnership, Qiagen obtains the rights to globally distribute current and future Verogen products. Our recognized bioinformatic capabilities will help improve the efficacy of biomarker signatures. From the first important step of DNA, RNA and protein extraction from biological samples, to novel testing technologies targeting single or multiple molecular variants, and software to analyze and interpret molecular data to deliver valuable insights. At the core of this strategy is a focus on five pillars of growth which are built on the companys leadership in sample technologies, the first step in any laboratory process. Multimodal Cancer Genomics Profiling Services - QIAGEN Try the Workflow Configurator. INOVIO is the first and only company to have clinically, that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a, tolerable immune response. +1 240 686 2222, The Netherlands QIAGEN and INOVIO expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIOs VGX-3100 for advanced cervical dysplasia, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIOs therapies, (*Complementary when referring to the US regulatory pathway. We believe we can optimize natural resource utilisation by developing vision sensors for . PLYMOUTH MEETING, PA., USA, and GERMANTOWN, MD., USA, and HILDEN, Germany, February 24, 2021 QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIOs therapies. QDI has assembled the worlds leading high-quality genomics Knowledge Base. Our all-in-one profiling solution offers the following benefits: Partner with us for expert guidance and dedicated service from Sample to Insight for profiling your samples today. Also in development are programs targeting HPV-related cancers, and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers, externally funded infectious disease DNA vaccine, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency. [40], Until the mid-2000s, QIAGEN was mainly a provider of sample technologies for the academic research market. Find out what a career at QIAGEN can offer you and explore our latest vacancies. Transparent, evidence-based NGS interpretation and reporting. Its critical that scientists and clinicians have the right tools to accelerate interpretation and deliver meaningful insights. Explore high-quality enzymes; now available as individual products. About us. Can you trust AI for germline variant interpretation? A convenient tool to build experimental workflows and find products to match your needs. QIAGEN pioneered HPV testing with the gold-standard. Trinamics has been active as a technical secondment agency since 2005. The pillars furthermore include the QuantiFERON franchise with its leading test for the detection of latent TB infection, the syndromic testing solution QIAstat-DX for the detection of multiple pathogens in a single run, and the high-throughput PCR-testing platform NeuMoDx, as well as the digital PCR testing technology QIAcuity. High-quality targeted viral and bacterial NGS using hybrid capture. [citation needed], In 2004, QIAGEN acquired key assets of Molecular Staging, Inc. Two years later, QIAGEN established its Asia regional headquarters in Shanghai. Visit the multimodal sequencing resource page for updates on our latest technologies, webinars and more. "As we advance our DNA medicines platform, we are always looking for ways to drive innovation with our own technology or that of a creative and accomplished partner. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Today 35,000 public citations reference Digital Insights products, and over 1,600,000 patient samples have been analyzed. Learn more about the options available to you and consult with experts about solutions for your projects. QIAGEN CLC Genomics Workbench 20 scalable desktop software for NGS data Introduction to CLC Genomics Workbench part2, Introduction to CLC Genomics Workbench-part1. Thank you for choosing QIAGEN. QIAseq UPXome RNA Library Kits. The company operates in more than 35 offices in over 25 countries. If you experience any issues with this process, please contact us for further assistance. Use the links below to find the information you need. QIAGEN is a pioneer in precision medicine and the global leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics that can detect clinically relevant genetic abnormalities to provide insights that guide clinical decision-making about diseases like cancer. Find out more about QIAGENs vision, identity and mission. The QIAGEN Knowledge Base is the most comprehensive source of publicly available curated omics data to support research, clinical trials and clinical testing labs. QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life - DNA, RNA and proteins. INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors. Sample technologies are used to collect samples of tissue, fluids, etc. Learn more. With our launching customers we are bringing or . The separation and purification of genetic information is a basic precondition for further application or analysis. Researchers report in Science that their live-imaging findings suggest long-distance communication between gene elements may be better than expected. ", Qiagen CEO Thierry Bernard added in a statement that the partnership"will drive the adoption of NGS in human identification as it will enable our customers to gain even better insights from their casework samples. Up to date protocols and list of COVID-19 testing and research solutions. Qiagen has 4 employees across 40 locations and $2.14 b in annual revenue in FY 2022. It is currently in two Phase 3 trials (REVEAL 1 and REVEAL 2), with the potential to become the first non-surgical treatment for advanced pre-cancerous cervical lesions associated with the virus (HPV-16 and HPV-18). The program includes workforce reduction and internal restructuring affecting approximately 10% of the company's 3,900 positions. Sample to Insight - QIAGEN QIAGEN Genomic Services overcomes these limitations by combining our optimized, multimodal panels with expert data analysis to support your cancer profiling needs. On August 21, the chairman of the company's supervisory board, Hkan Bjrklund, stepped down to be immediately replaced by Lawrence Rosen. Up to date protocols and list of COVID-19 testing and research solutions. At QIAGEN N.V., we promise to treat your data with respect and will not share your information with any third party. This will ultimately strengthen justice systems all over the world.". . Get inspiring content today with a free face mask. Qiagen N.V. - QIAGEN announces Digital Partner Program with five Sie mssen den Aktivierungslink anklicken, um Ihr Abonnement abzuschlieen. Vice President Head of Corporate Communications and Investor Relations, Germany The capabilities of this combination enable clinicians to rapidly identify alterations in tumors and receive oncologist-ready variant interpretation reports, informing treatment decisions for patients with advanced solid tumors. [20] In 2015, QIAGEN acquired AdnaGen's circulating tumor cell enrichment technology. [22], In March 2015, a management buyout of QIAGEN Marseille led to the creation of HalioDx. The demo report gives you an example of the kinds of data you will receive in the final report from your Multimodal Cancer Genomics Profiling Services. QIAGEN Digital Insights delivers expert curated genomic and clinical knowledge, software and services for scientists and clinicians to improve insights, accelerate decision and deliver better outcomes. The first group of five new partnerships involves DNAnexus, GNS Healthcare, Personal Genome Diagnostics, ThermoFisher Scientific, and the Wellcome Sanger Institute. Lusoco is a spin-off company of the University of Eindhoven. We integrate sustainable practices into every aspect of our business, from reducing our environmental impact and creating healthy, high performance workplaces to being a good corporate citizen. +31 773 55 66 66, Phoebe Loh Sie mssen den Aktivierungslink anklicken, um Ihr Abonnement abzuschlieen. In May 2022, QIAGEN strengthened its sample technologies business and acquired the majority stake in enzymes provider BLIRT S.A. QIAGEN is a worldwide provider of molecular sample insights. Working closely with QIAGENs Project Insight services, GNS Healthcare will advance AI-based products and services, including Gemini The. All Rights Reserved. Our experience in developing liquid biopsy-based diagnostic solutions for precision medicine in immuno-oncology will help INOVIO address a larger unmet medical need, said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development at QIAGEN. In May,Verogenannounced that it had partnered with Eurofins to implement NGS into routine forensic DNA casework. [27] In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform. By providing your email address below, you are providing consent to QIAGEN N.V. to send you the requested Investor Email Alert updates. [citation needed], Infectious Diseases: QIAGEN offers several comprehensive test panels for the detection of bacterial and viral pathogens. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading Risk Factors contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.